At a glance
- Originator Taisho Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Mar 2001 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 18 Apr 1997 No-Development-Reported for Cancer in Japan (Unknown route)
- 26 Oct 1995 New profile